Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just cover! No amount of FEAR, UNCERTAINTY, OR DISTORTION WILL CHANGE THE OUTCOME OF THE NEXT RESULTS!
Leo should use Remde plus standard of care in both moderate and severe cv19 patients for the controlled group.
For critically ill patients, it will be Bril plus standard of care vs standard of care alone.
Mild is a gimme.
Big Pharma will be salivating once the lung in-vivo assay comes out. That's GOING TO BE GREAT AND THAT I CAN GUARANTEE TO YOU ALL! Imagine Bril working in and saving people's lives in severely and critically ill patients with ARDS?! Wow!!
My gold standard? Leaving no stone unturned even if IPIX was listed on OTC. Bril has up to $10b clinical application potential, imo. I'm in at 7, 9,... Thank you!
GB
The gold standard means government and/or grant funding are coming our way. Oh, who is to say that Leo doesn't have a private placement funding lined up already to fund Phase II trial in mild, moderate, severe, and critically ill patients if there's a delay in funding? That's not counting a bp partnership or acquisition after the lung in vivo assay! YIKES!
He's no dummy when it comes to securing funding with Bril being the best THERAPEUTIC AND PROPHYLAXIS COMPOUND THERE IS IN COMBATING SARsCoV2! Oh, man! This company will trade over $500m in no time.
Checkmate! Bril is a BLOCKBUSTER DRUG FOR COVID.
It's looking like Bril is your flagship drug with multiple clinical indications in areas such as immunotherapy, pandemic virus, bacterial-resistant infection, autoimmune disease, and etc.etc.
Bril is already a potential blockbuster drug in the making for CV19. And I'd peg their entire value as potentially at least $10 billion alone for any pharma to acquire IPIX. The CEO can throw in this Kevitrin for free and sell the company for $1.5B, or look to MERGE WITH ANOTHER COMPANY so it can expand its Bril's clinical pipeline. Jmo.
Great results should be done and out very soon. The question is, what are you going to do with that information? Now! And not after the facts.
The report below.... of contenders vs pretenders. Bril is our juggernaut character from X-men.
https://www.genengnews.com/category/covid-19-candidates/covid-19-antiviral/
A lot of tests needed need to be done with RBL. There were five bullet points such as EC50, combination, dosing concentration, etc.etc., in that particular pr. Don't sweat it. It's going to be great-- the fact that it already worked on human kidney cells assay then the biding in human lung epithelial cells will be just as good or even better in reducing the viral titer of SARsCoV2. This RBL testing takes time. You didn't get the memo? Please try to relax. Just enjoy and enjoy process. I hope you weren't shorting this company.
I would worry about what outcome happens next when phase II is initiated after funding, Imo. The outcome is going to be a very big one on that one in humans! GL2U
You are "pro"? Am I am curious what makes you a real pro? Why use 10MM only for Bril for phase 2 ready? Why not 200MM or 300MM if the addressable market is worth at least what? $10b for cv19 alone? The government alone is more likely to throw 60 million to 70 million minimum to fund Phase II! Assuming if they just want the anti-inflammatory therapeutic benefit alone without the preventive antiviral application.
And that doesn't include other clinical potential clinical applications like AKI and or other pandemics that de-risk Bril acquisition. Do you even understand business valuation since repurposing a drug in phase II for this company for cv19 could increase their market cap by at least a minimum of 500 million to 700 million? A big pharma alone could get a $5 to 8 billion market cap increase easily by announcing II trial initiation.
I'm just very curious about what makes yourself what makes you a pro? I'm leaving the science out of this conversation for now just to be fair.
Sanofi and Regeneron's Kevzera showed no therapeutic benefit in CV19 patients. I am not shocked. At all. So that leaves two big pharma with no therapeutic drug to address CV19. Arthritic drugs will not work in my opinion.
Amgen is repurposing its Otesla drug to address respiratory illness as preventative therapy. Just like Bril, Ostela shares somewhat similar anti-inflammatory properties in inhibit PDE4. But Bril has more with its 3-in-1 action.
It's looking like Bril is an i-o platform with potentially treating AKI as well. This is a blockbuster drug in the making once we get results back and phase II gets going, IMO.
Two pathways so far: cAMP + IFnB. Lastly, my previous tweet a few weeks back to postulate how Bril exhibits its antiviral effects(2) was posted here as well and the recent pr confirmed it. We have a great science here in Bril!
My hypothesis is slightly different from Spike protein and SARsCoV2's cell membrane, which I referred the E -envelope that is a bilayer lipid membrane. In my previous contributions, I mentioned that Bril inhibits viral replications by ENTRY AND REPLICATION; and the MOA of actions will not only involve the virus wall membrane that most think here but it will also include the S-protein. The spike protein of SARScoV2 has always been the mediator of how the virus enters, infect, and induce the pathogenesis into the host cells. So S-protein structure consists of S1 AND S2, for receptor binding and for fusion, respectively, that interfaces with the human ACE2 protein receptor. This S-spike matches up well with Bril since both contain hydrophilic and hydrophobic regions. Bril amphipathic regions simply bind to S-protein. Like-to-like binding affinity molecules between Hydrophobic and hydrophilic. This is remarkable!
What happens next is your positive curvature (convex) change in the physicochemical properties of S-protein binding to Bril. So this distortion of the shape hinders S-protein ability to bind to ACE2 receptor into the host cells. That's your inhibition of antiviral via entry. The last one is inhibition by replication. This the portion where Bril's antimicrobial peptide degenerates, compromises, or melts the bilayer membrane (known as Envelope Protein or E- protein), to make the wall porous and creating a negative curvature that it ultimately inhibits RNA replication. Apoptosis happens!
But we shall see what UNIVERSITY top virologists say!
He is right about not understanding the basic Pharmacologygy 101 based on PK/PD, but that makes you wrong as well with Bril not being used as a stand-alone drug. It'malarkey to say just the drug has multiple MoAs it excluded from being used as a stand-alone drug. Oh my goodness, "'Dr.J'."
You don't know that. Do you work with him? What made you so sure? And you want to Bril in combination with corticosteroids plus cuz? A triplet combo? Are you out of your mind? Wtf?!
Anytime. Basically, Ipix just found out that Bril could be used for treating patients with AKI besides inhibiting the proliferation of SARsCoV2 in kidneys!
Renal failure has been associated with a percentage of covid19 patients.
This is very big. SARsCoV2 is implicated in viral-induced kidney inflammation leading to exacerbation of AKI with severe acute tubular necrosis. Worsening of oxidative stress is also involved along with microvascular injury. Bril just potentially expanded its clinical application in AKI patients with today's results! ACE2 receptors in kidneys are more prevalent than in lungs, mind you.
The organ crosstalk also happens between injured lungs, kidneys, and heart that worsens their subclinical conditions.
Ivermectin is another hyped up drug (by parasites and criminals?) that is very unlikely to work in humans just like HCQ. Anti-parasitic drug. Same results--with very little therapeutic benefits.
The above drug is also given to dogs for heartworms. Know what you own with Bril that has already proven it's safety and efficacy profiles in human clinical trials.
TAGB
To Leo,
We have been a firm believer of Bril for cv19 since early March, as per my extensive due diligence. We placed our long bets on the table to support your company with high confidence and high assertion of potential success in addressing the unmet need of CV19 pandemic.
Keep up the great work. We are also expecting funding grants and/or partnerships to happen to help advance Bril as both therapeutic and prophylaxis drug. Thank you.
Best,
TAGB.
P.S.
We are curious if Remde will be used as the placebo-controlled patients when PII commences?
Besides the IV version, we'll just have to wait and see if IPIX will make an oral pill version of Bril in the future. The oral pill will work best for preventative as we as your mild cases of cv19 population.
I'm looking forward to the next great results very soon and the update of when the phase II trial will begin, to go with the government funding or grants. A partnership is a very likely scenario too.
Lastly, maybe Ipix should should use Remde as their controlled placebo. Or Remde + Tocilizumab combination?
TAGB
You wrote:
Thanks, nice post. I agree with most of your comments, but oral Brilacidin has been shown numerous times to not be absorbed systemically.
First of all, the IV portion of Bril is systematically absorbed with 100% bioavailability in plasma protein of the blood! However, you are right about the IBD/UC po drug intentionally made by Oralogic to treat IBD/UC and to have very limited systemic absorption, as such it was intended to go target the colon. But at this point, the po version for IBD/UC will not be repurposed, so that leaves us with the IV option only for the interim period. The possibility is there to come up with po form for prophylaxis to prevent and even address mild cv19 occurrence. But that's another story just as your inhaler idea as well. However, repurposing the po version may give us another opportunity in the GI portion since some patients are experiencing abnormalities with thickening of the bowel wall and ischemia. SARsCoV2 viral replication as the culprit in the intestine as the explanatory cause.
I'm not sure why you brought this up?
"I am not aware of any reports linking the GI disorder with later severe pulmonary failure."
SARsCOV2 maybe RNA based compared to influenza but they do not share the same homology from each other in terms of structure. SARsCOv is 83% and MERsCoV is 56% and a big drop off from the rest of other flu pandemics such as H1N1, etc., etc. But my point was, if the Juggernaut (character) Bril can address CV19, then it's more likely to be the key or the backbone of future therapeutic for pandemic flu to shorten the duration or episode that leads to their pathogenesis.
Do you think the LEO doesn't read this site? Obviously, I did mention Remdesivir as a potential placebo to send shock waves, but it's a coincidence that the drug was mentioned too. That drug has serious renal and liver concerns with cv19 patients and a much higher death rate than what was originally disclosed that came out of China.
We have a great drug here and I'm very confident for damn good success in the human lungs and other results we are waiting. Binding should be much faster with h l epithelial cells. Sp should easily fill the 1.84 gap. But no doubt with any funding we will hit $3. Let's hope we get multiple grants and big funding from the government so we can get to $4+ after the trial is initiated. GLTA! Black Diamond in here.
TAGB
Clinical applications for Bril would include but not limited to prophylaxis, therapeutic, and as an adjunct combo to any complementary drug out there. That's practically three applications, but two should be enough since the IV portion could be easily repurposed for moderate, severe, and critically cv19 patients. The oral pill should suffice for many as a preventative and for mild or even moderate patients, to halt the progression to severe and critically ill patients.
Ipix could send shock waves if they decide to use Remdesivir as the placebo. They should. Practically, all nucleotide inhibitors are now useless! Bril is more likely to be effective than Leronlimab, Imo, since upregulation of defensin mimetics is enough to trigger an adaptive immune response to make its "indirect" antiviral effects but also in addressing severe patients with pneumonia and/or sepsis.
Now it will be interesting how TIH will look at this in terms of funding.
Will they run the IV portion only Or will they the po version as well for preventative? I expect grants and or funding to happen soon. A partnership could happen too as well, IMO. BRIL SHOULD ALSO WORK FOR OTHER PANDEMIC FLU, which is another business opportunity for IPIX.
Not worried about the next readout. It's in the bag already, some are just a bit slow or unable to assess or foresee things rather quickly; Pass the salt please!
If you find yourself betting against the company, what are you going to do about it? Checkmate! Both sides will catch fire and it's just a matter of time before this sp hits $1, $2, or higher. The valuation is very cheap here with IPIX and it's long overdue for a major correction!
My assumptions about their science have been spot on. The next readout will confirm that as well. GLTA.
We appreciate your business!
TAGB
100% legal. They're not employed as corporate insiders, and possession of material non-public information only applies to insiders' knowledge of pending or potential M&A.
Another great confirmation today! However, the real meaty info will be due out soon that will propel the sp to about $300mc or more. Funding grants and/or partnerships with pharma is up and very likely, to go with a status update with PhaseIIb trial initiation! IND needs to be submitted first and announced ahead of human trials.
Bril is unorthodox antiviral effects that are unique, which also gives it more opportunities for other pandemic flu out there. We should trade over $1 very soon.
Excellent contribution. Ipix will easily trade over $1 when the news come out.
Remde lacks antiviral to trigger innate..necessary to activate an adaptive immune response. With Baricitinib? That's just mad science,imo. Toxicities issue will kill the combo I doubt the two combined will be any better.
A new but old scripted play from the " parasites " playbook? Safer? Says who? You? It has never been tested in humans, so yes, safer maybe in vitro assay and it looked great! And since you are well versed, you should know that antibodies in vitro vs SARsCoV2 aren't necessarily transferrable to humans. Let alone, will it guarantee safety and immunity to the subsequent virus infection. You never heard of mutagenicity? Well, at least Brilacidin is naturally produced in human epithelial cells so it's safe too. It goes from innate to adaptive immune reponse. Take notes. Vaccines? It may not be 100% effective as prophylaxis,but it's still safe.
I'm looking for an adjuvant to what BARDA and JNJ are currently working on for a vaccine. They're still in the discovery stage so we are still good. Their preclinical starts in Sept. Three shots on goal with Bril imo.
Yes, I have but very little with K.
I take a "leave no stone unturned" approach when it comes to investing." I screened cv19 companies and found out about this company and Bril. Bril's science was unique and it fascinated me so I devoted an extensive due due dili. Definitely more than meets the eye here when it comes to combating cv19. A hidden gem that most didn't know on.. that exist. When it comes to cv19, TIH doesn't care where the company is listed, it only cares about getting the drug advanced and solving the cv19 pandemic.
I would love to see CEPI fund IPIX too. I'M sure they are already aware of Brilacidin already based on a previous publication last March.
I have no doubt that IPIX will go parabolic. The company 's mc is 30mc. That's very cheap! Brilacidin will be good for CV19 in all phases of patients, IMO. The upregulation of hdm in human epithelial cells, more so in human clinical trials will prove substantially beneficial in dampening the cytokine and chemokine storm induced by the virus in alveolar type II cells in the lungs for patients with severe and critically ill patients, with or without pneumonia. This drug does both. Activate innate followed by adaptive immune response by also reducing RANTES via induction of IFN-b( IFN-beta).
Cydy's leronlimab appreciated $1b on cv19 alone, and that is without funding. Now imagine what Ipix can do when the results are released! Over 350m mc easily, and that's over $1. Parasites and the criminal didn't get the memo.
Time to cover short before you lose everything. My free "pro" advice to you.
Phase 2b, I hope, instead of regular Phase II as cited on 10Q yesterday. With Bril being dose-dependent, the dosing could be bi-weekly! I can't remember the dosing with ABSSSI, but that could be the starting point or close to it. The previous pr's verbiage led me to believe that they will do both P2B/PIII here in the US and Europe for therapeutic. So who knows. It would be great if our clinical trials are coupledn together just like cydy's leronlimab.
The parasites are scared shix. This company will easily trade over $1 and that's 300m mc at a bare minimum before they even initiate PII trial. There's no telling how high this will go when they get the grants and/or fundings. IF the drug is going to be used as prophylaxis and therapeutic, to go with a potential adjuvant with BARDA and JNJ collab vaccine in the discovery stage right now, the mc will push above $1b for those indications. At a minimum, I'll the company trading over $700m.
Anyway, I just checked your inbox messages for the first time today. And I guess, phase II planning - the 10Q answered your question. The second question about the pin popping the balloon analogy, my answer is No. My hypothesis is slightly different from Spike protein and SARsCoV2's cell membrane, which I referred the E -envelope that is a bilayer lipid membrane. In my previous contributions, I mentioned that Bril inhibits viral replications by ENTRY AND REPLICATION; and the MOA of actions will not only involve the virus wall membrane that most think here but it will also include the S-protein. The spike protein of SARScoV2 has always been the mediator of how the virus enters, infect, and induce the pathogenesis into the host cells. So S-protein structure consists of S1 AND S2, for receptor binding and for fusion, respectively, that interfaces with the human ACE2 protein receptor. This S-spike matches up well with Bril since both contain hydrophilic and hydrophobic regions. Bril amphipathic regions simply bind to S-protein. Like-to-like binding affinity molecules between Hydrophobic and hydrophilic. This is remarkable!
What happens next is your positive curvature (convex) change in the physicochemical properties of S-protein binding to Bril. So this distortion of the shape hinders S-protein ability to bind to ACE2 receptor into the host cells. That's your inhibition of antiviral via entry. The last one is inhibition by replication. This the portion where Bril's antimicrobial peptide degenerates, compromises, or melts the bilayer membrane (known as Envelope Protein or E- protein), to make the wall porous and creating a negative curvature that it ultimately inhibits RNA replication. Apoptosis happens!
But we shall see what UNIVERSITY top virologists say!
The man is a genius. Hats off to him. Not many are capable of understanding science, finance, and accounting(CPA)--all in the same breath as he does. And that's why he's so fiscally attuned in keeping this company running lean and mean for a long time now.
I would also caution everyone that if there is no news this coming Monday, don't be disappointed. The great news is just inevitable, IMO.
The next set of great news will be very robust and very positive news to go with "TIH" footing bill, which will also maximize any potential exclusive licensing partnership or buyout solicitation from pharma, if any is in the works.
GLTAL!
Spike protein which contains an RBD, recognizes and binds to the human host cell is known as ACE2 receptor as the interface to enable its viral pathogenesis, is made up of both hydrophilic and hydrophobic bound by hydrogen bonds! So if Bril has amphiphilic regions, then it only makes sense to postulate that it can insert itself to the S-protein besides your KNOWN typical bilayer lipid membrane of the envelope protein (degeneration causing positive curvature ). Two MOAs potentially with viral inhibitions. Inhibition by entry and replication.
Nothing is that easy for many of us with what is (science) not fully given or understood as a finished product. You'll have to employ your own hypothesis based on what clinical data or analysis you can derive and deduct with what's out there. Your ability to digest and extrapolate both known and unknown data and postulate an outcome will determine your success.
The parasites and criminals ' textbook play. Avoid science but fill in the untruthful spaces.
Yes, I love this drug ever since I discovered this company while I was screening for my CV19 plays. The TRIDENT 3-in-1 action approach being an immunoregulator drug that it was a huge plus and a distinct advantage over those protease inhibitors that are being repurposed. Leave no stones unturned regardless of where the company is listed. Simply put, the compound HDMs work in all types of pandemics, and the MOA if its antiviral is more likely being evaluated by that University? JHU or Pennsylvania U?
The results are going to be good if not great with Bril's amphiphilic ability to bind to S-protein to inhibit viral entry to host cells via ACE2, but also degenerates the E-membrane of SARsCoV2 to inhibit viral replications. Jmha and opinion.
Funding could amount to 40m to 60m or more since Bril has the potential to be an adjuvant to oral any vaccine, if not a stand-alone and/or combination drug. So I totally agreed with you. The best risk to reward investment play for all cv19 therapeutic drugs. There's no doubt in my mind that this drug will work! GLTA!
Don't fight the TIH that prints the money and makes Bril more valuable in addressing the unmet need of cv19 patients. But TIH also enhances the chances and visibility of IPIX for any potential opportunities unbeknownst to us.
Ah, no worries. I'm glad I can simplify things to help understand what Bril brings to the table when it comes to therapeutic and prophylaxis benefits in SARsCoV2 patients.
A chain of reaction that's viral-induced leads to much SARsCoV2 pathogenesis. For instance, low oxygenated blood due to pulmonary and/or respiratory illness is the main leading cause of why patients being intubated. If that's not worse enough, those who are hypoxic -- some patients develop coagulopathy. Then hypoxia causes renal failure like what you cited.
Two pathways that make Bril exhibits is antiviral effects induces its anti-inflammatory properties.
1. cAMP pathway through PDE4
2. IFNb pathway -indirect antiviral that also inhibits RANTES!
Looks like the "parasites" and " criminals" here shorted this company without really understanding the science behind Bril.
As always, we appreciate the business.
We are all just waiting now for the show stopper! The masterpiece. Someone is going for broke.
Nothing has changed. As predicted before, they are starting the Phase II trial. Maybe phase 2b. I was hoping it would be both PII and Phase III. But it's a great thing!
EC50, potential combo, frequency dosing, determining efficacy concentration without cytotoxicity, and post-entry inhibitory effects are the last readout. The narrative hasn't changed with Bril looking to be a direct antiviral (and indirect INFb pathway), an anti-inflammatory, and antimicrobial. Simply put, any drug out there to have a therapeutic benefit, it has to have immunomodulatory properties to be even beneficial to addressing anti-inflammatory portion associated with cytokine storm (via downregulation). How do you like them peaches?
Now grant funding, and/or pharma partnership is very likely to happen. IND announcement is due after the results come out! Science with Bril is real and TIH (the invisible hand) is printing money to fund this trial.
AGB